One man's side effect is another man's therapeutic opportunity: targeting Kv7 channels in smooth muscle disorders

Research output: Contribution to journal › Journal article › Research › peer-review

Standard

One man's side effect is another man's therapeutic opportunity : targeting Kv7 channels in smooth muscle disorders. / Jepps, Thomas Andrew; Olesen, S P; Greenwood, I A.

In: British Journal of Pharmacology, Vol. 168, No. 1, 2013, p. 19-27.

Research output: Contribution to journal › Journal article › Research › peer-review

Harvard

Jepps, TA, Olesen, SP & Greenwood, IA 2013, 'One man's side effect is another man's therapeutic opportunity: targeting Kv7 channels in smooth muscle disorders', British Journal of Pharmacology, vol. 168, no. 1, pp. 19-27. https://doi.org/10.1111/j.1476-5381.2012.02133.x

APA

Jepps, T. A., Olesen, S. P., & Greenwood, I. A. (2013). One man's side effect is another man's therapeutic opportunity: targeting Kv7 channels in smooth muscle disorders. British Journal of Pharmacology, 168(1), 19-27. https://doi.org/10.1111/j.1476-5381.2012.02133.x

Vancouver

Jepps TA, Olesen SP, Greenwood IA. One man's side effect is another man's therapeutic opportunity: targeting Kv7 channels in smooth muscle disorders. British Journal of Pharmacology. 2013;168(1):19-27. https://doi.org/10.1111/j.1476-5381.2012.02133.x

Author

Jepps, Thomas Andrew ; Olesen, S P ; Greenwood, I A. / One man's side effect is another man's therapeutic opportunity : targeting Kv7 channels in smooth muscle disorders. In: British Journal of Pharmacology. 2013 ; Vol. 168, No. 1. pp. 19-27.

Bibtex

@article{0a350b69385d40f4acda84f99225776f,
title = "One man's side effect is another man's therapeutic opportunity: targeting Kv7 channels in smooth muscle disorders",
abstract = "Retigabine is a first in class anticonvulsant that has recently undergone clinical trials to test its efficacy in epileptic patients. Retigabine's novel mechanism of action - activating Kv7 channels - suppresses neuronal activity to prevent seizure generation by hyperpolarizing the membrane potential and suppressing depolarizing surges. However, Kv7 channels are not expressed exclusively in neurones and data generated over the last decade have shown that Kv7 channels play a key role in various smooth muscle systems of the body. This review discusses the potential of targeting Kv7 channels in the smooth muscle to treat diseases such as hypertension, bladder instability, constipation and preterm labour.",
author = "Jepps, {Thomas Andrew} and Olesen, {S P} and Greenwood, {I A}",
note = "{\textcopyright} 2012 The Authors. British Journal of Pharmacology {\textcopyright} 2012 The British Pharmacological Society.",
year = "2013",
doi = "10.1111/j.1476-5381.2012.02133.x",
language = "English",
volume = "168",
pages = "19--27",
journal = "British Journal of Pharmacology",
issn = "0007-1188",
publisher = "Wiley",
number = "1",

}

RIS

TY - JOUR

T1 - One man's side effect is another man's therapeutic opportunity

T2 - targeting Kv7 channels in smooth muscle disorders

AU - Jepps, Thomas Andrew

AU - Olesen, S P

AU - Greenwood, I A

N1 - © 2012 The Authors. British Journal of Pharmacology © 2012 The British Pharmacological Society.

PY - 2013

Y1 - 2013

N2 - Retigabine is a first in class anticonvulsant that has recently undergone clinical trials to test its efficacy in epileptic patients. Retigabine's novel mechanism of action - activating Kv7 channels - suppresses neuronal activity to prevent seizure generation by hyperpolarizing the membrane potential and suppressing depolarizing surges. However, Kv7 channels are not expressed exclusively in neurones and data generated over the last decade have shown that Kv7 channels play a key role in various smooth muscle systems of the body. This review discusses the potential of targeting Kv7 channels in the smooth muscle to treat diseases such as hypertension, bladder instability, constipation and preterm labour.

AB - Retigabine is a first in class anticonvulsant that has recently undergone clinical trials to test its efficacy in epileptic patients. Retigabine's novel mechanism of action - activating Kv7 channels - suppresses neuronal activity to prevent seizure generation by hyperpolarizing the membrane potential and suppressing depolarizing surges. However, Kv7 channels are not expressed exclusively in neurones and data generated over the last decade have shown that Kv7 channels play a key role in various smooth muscle systems of the body. This review discusses the potential of targeting Kv7 channels in the smooth muscle to treat diseases such as hypertension, bladder instability, constipation and preterm labour.

U2 - 10.1111/j.1476-5381.2012.02133.x

DO - 10.1111/j.1476-5381.2012.02133.x

M3 - Journal article

C2 - 22880633

VL - 168

SP - 19

EP - 27

JO - British Journal of Pharmacology

JF - British Journal of Pharmacology

SN - 0007-1188

IS - 1

ER -

ID: 44304682